最新アルツハイマー病研究 ―病態解明から治療薬開発まで―

出版社: ワールドプランニング
著者:
発行日: 2001-02-15
分野: 臨床医学:内科  >  精神医学
ISBN: 9784948742406
電子書籍版: 2001-02-15 (第1版第1刷)
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,200 円(税込)

商品紹介

アルツハイマー病の原因はなにか?遺伝するのか?発症の引き金となる病因はなにか?脳内にどのような変化が起こるのか?治療の手立てはあるか?実現の可能性はあるのか???アルツハイマー病の原因→病因→症状へと進むメカニズムはどこまで解明されているか? 治療薬の開発は進んでいるか? これらのすべてにお答えします!

目次

  • 表紙
  • 序文
  • 執筆者一覧
  • 目次
  • 第1章 アルツハイマー病の病態
  • はじめに
  • I. アルツハイマー病研究の歴史
  • II. 神経病理学的所見
  • III. 神経化学的所見
  • IV. 分子生物学的所見
  • V. 分子遺伝学的研究
  • VI. アルツハイマー病の成り立ち
  • おわりに
  • 第2章 形態学的観点から
  • 1. アミロイドβタンパク
  • はじめに
  • I. 老人斑からアミロイドβタンパクへ
  • 1. アルツハイマー病脳におけるアミロイド沈着
  • 2. アミロイドβタンパクの同定
  • II. アミロイドβタンパクからアミロイド前駆体タンパクへ : 遺伝子へのアプローチ
  • 1. アミロイド前駆体タンパク
  • 2. アミロイド前駆体タンパクからアミロイドβタンパクの生成
  • III. アミロイドβタンパクとアミロイド前駆体タンパクの分布と局在
  • 1. 形態
  • 2. 局在と由来の検索
  • IV. アミロイド前駆体タンパクの遺伝子変異と家族性アルツハイマー病
  • V. アルツハイマー病におけるアミロイドβタンパクとアミロイド前駆体タンパクの機能
  • 1. Aβの特性
  • 2. Aβ・APPと神経細胞変性
  • VI. アミロイドβタンパクと他のアミロイド構成物質との関連
  • 1. アミロイドPコンポーネント
  • 2. アポリポタンパクE
  • 3. プレセニリン - 1
  • おわりに
  • 2. 神経原線維変化
  • はじめに
  • I. 神経細胞の骨格タンパク : 微小管とタウタンパク
  • II. 神経原線維変化とタウタンパクの関係
  • III. タウタンパクの異常リン酸化
  • IV. 神経原線維変化とユビキチン
  • V. 神経原線維変化に含まれるその他のタンパク
  • VI. glial fibrillary tangle
  • VII. 封入体筋炎における神経原線維変化類似構造
  • おわりに
  • 第3章 生化学的観点から
  • 1. 神経伝達物質異常
  • I. 神経伝達物質
  • 1. 神経伝達物質とは
  • 2. 神経伝達物質研究の意義
  • II. アルツハイマー病患者死後脳における神経伝達物質の変化
  • 1. コリン作動系
  • 2. セロトニン作動系
  • 3. ノルアドレナリン系作動系
  • 4. ドーパミン作動系
  • 5. 神経ペプチド
  • 6. アミノ酸
  • 7. その他
  • III. 病因論的観点から
  • IV. 診断論的観点から
  • V. 治療論的観点から
  • おわりに
  • 2. セカンドメッセンジャー
  • はじめに
  • I. カルシウムホメオスタシス
  • II. カルシウム結合タンパク
  • III. アルツハイマー病におけるカルシウム結合タンパク
  • IV. アミロイドβタンパクと神経細胞死
  • おわりに
  • 3. 精神神経免疫
  • はじめに
  • I. 免疫系の概要
  • II. ミクログリア
  • III. 補体系
  • IV. サイトカイン
  • V. 急性炎症物質
  • VI. 抗炎症薬治療
  • おわりに
  • 第4章 遺伝学的観点から
  • 1. 家族性アルツハイマー病の原因遺伝子
  • はじめに
  • I. アミロイド前駆体タンパク遺伝子
  • II. プレセニリン - 1およびプレセニリン - 2遺伝子
  • III. 家族性アルツハイマー病と危険因子
  • IV. 現在検討されているアルツハイマー病に関連する他の遺伝子
  • おわりに
  • 2. プレセニリン
  • はじめに
  • I. プレセニリン - 1およびプレセニリン - 2遺伝子のエキソン構造
  • II. プレセニリン - 1および2遺伝子変異と家族性アルツハイマー病
  • III. プレセニリン - 1遺伝子と孤発性アルツハイマー病
  • IV. プレセニリン - 1および2遺伝子産物タンパクとアルツハイマー病発症機序に関連する研究
  • 1. プレセニリン - 1および2タンパクが受容体である可能性
  • 2. プレセニリン - 1タンパクが膜イオンチャネルである可能性
  • 3. プレセニリン - 1および2タンパクが物質輸送に関与している可能性
  • 4. プレセニリン - 1および2タンパクが神経細胞死抑制の過程に機能を有している可能性
  • V. プレセニリン - 1トランスジェニックマウスモデル
  • おわりに
  • 3. アポリポタンパクE
  • はじめに
  • I. 機能と役割
  • II. アポEの遺伝子多型性
  • III. アルツハイマー病におけるε4保有者の頻度
  • IV. ε4のアルツハイマー病発症年齢への関与
  • V. ε2の保護的役割
  • VI. 臨床症状との関連
  • VII. 薬物治療とアポリポタンパクE
  • VIII. ε4の疾患特異性
  • IX. その他のアポEに関連する物質の研究
  • おわりに
  • 第5章 臨床的観点から
  • 1. 生物学的診断マーカー
  • はじめに
  • I. タウタンパク
  • II. アミロイドβタンパクおよびアミロイド前駆体タンパク
  • III. α1 - アンチキモトリプシン
  • IV. 神経伝達物質
  • 1. アセチルコリン
  • 2. ドーパミン
  • 3. ノルエピネフリン
  • 4. セロトニン ( 5 - HT )
  • 5. γ - アミノ酪酸
  • 6. 神経ペプチド
  • V. 免疫系
  • おわりに
  • 2. 機能的画像検査
  • はじめに
  • I. PET
  • 1. 原理
  • 2. PETを用いた研究
  • 3. 問題点
  • II. functional MRI
  • 1. 原理
  • 2. fMRIを用いた研究
  • 3. 問題点
  • おわりに
  • 3. 新たな薬物療法
  • はじめに
  • I. アルツハイマー病の成因論と治療薬の開発
  • II. わが国のアルツハイマー病に対する薬物療法の現況
  • III. 開発段階のアルツハイマー病治療薬
  • 1. ACh系作動薬
  • 2. セロトニン系作動薬
  • 3. 神経ペプチド系作用薬
  • 4. 神経成長因子関連作用薬
  • 5. 神経伝達系に多面的に作用する薬物
  • 6. その他の候補薬物
  • IV. 今後の治療薬開発の展望
  • 第6章 関連疾患 : 他の初老期痴呆
  • 1. ピック病
  • はじめに
  • I. 神経病理学的所見
  • II. 免疫組織化学的所見
  • 1. ピック嗜銀球
  • 2. ピック細胞
  • 3. グリア内封入体 ( グリア変性 )
  • III. 神経免疫学的検討
  • 1. 活性化ミクログリアの浸潤
  • 2. 補体の活性化
  • IV. タウタンパクの生化学的所見
  • V. 分子遺伝学的研究
  • 1. アポリポタンパクE
  • 2. タウタンパク遺伝子
  • 3. アポトーシス
  • VI. 神経伝達物質
  • おわりに
  • 2. クロイツフェルト - ヤコブ病
  • はじめに
  • I. プリオン病とは
  • II. クロイツフェルト - ヤコブ病の臨床および検査所見
  • 1. 孤発性CJDおよび家族性CJD
  • 2. 新変異型CJD
  • 3. 医原性CJD
  • III. アミロイドの神経毒性と分子シャペロン
  • おわりに
  • 3. レビー小体病
  • はじめに
  • I. レビー小体病の分類
  • II. びまん性レビー小体病
  • III. 臨床診断
  • IV. 臨床検査
  • V. 病理学的所見
  • VI. 神経化学的所見
  • VII. 分子生物学的研究
  • おわりに
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 アルツハイマー病の病態

P.13 掲載の参考文献
1) 新井平伊 : アルツハイマー型痴呆における神経伝達物質の変化. 精神経誌, 90 : 863-868 (1988).
2) 新井平伊 : Alzheimer病 ; 成因・診断基準と臨床的特徴. Mebio, 13 : 26-37 (1996).
3) 田平武 : アルツハイマー型痴呆の遺伝. カレントテラピー, 15 : 55-60 (1997).
4) 植木彰 : アポリポ蛋白とアルツハイマー病. Dementia, 10 : 146-158 (1996).

第2章 形態学的観点から

P.38 掲載の参考文献
1) Barrow CJ, Yasuda A, Kenny PTM, Zagorski MG : Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease. J Mol Biol, 225 : 1075-1093 (1992).
2) Cohen AS, Calkins E : Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature, 183 : 1202-1203 (1959).
4) Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, et al. : Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β-amyloid fibrils. Acta Neuropathol, 84 : 225-233 (1992).
5) Games D, Adams D, Alessandrini R, Barbour R, et al. : Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature, 373 : 523-527 (1995).
8) Glenner GG, Wong CW : Alzheimer's disease ; Initial report of the purification and characterization of a novel cerebrovascular amyroid protein. Biochem Biophys Res Commun, 120 : 885-890 (1984).
9) Goate A, Chartier-Harlin MC, Mullan M, Brown J, et al. : Segregation of amissense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349 : 704-706 (1991).
10) Haass C, Selkoe DJ : Cellular processing of β-amyloid precursor protein and genesis of amyloid β-peptide. Cell, 75 : 1039-1042 (1993).
11) 星美奈子 : アルツハイマー病研究への新しい視点 ; Aβ1-42とアセチルコリン. 生化学, 69 : 181-187 (1997).
12) Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, et al. : Visualization of Aβ42 (43) and Aβ40 in senile plaques with end-specific Aβ monoclonals ; Evidence that an initially deposited species is Aβ42 (43). Neuron, 13 : 45-53 (1994).
15) 川原正博, 黒田洋一郎 : アルツハイマー病βアミロイド蛋白質によるイオンチャンネル形成と神経細胞死. 蛋白質・核酸・酵素, 42 : 2002-2010 (1997).
16) Kimura M, Arai H, Takahashi T, Iwamoto N : Amyloid-P-component-like immunoreactivity in β/A4-immunoreactive deposits in Alzheimer-type dementia brain. J Neurol, 241 : 170-174 (1994).
18) Masters CL, Multhaup G, Simms G, Pottgiesser J, et al. : Neuronal origin of a cerebral amyloid ; Neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J, 4 : 2757-2763 (1985).
19) Muller U, Cristina N, Zhi-Wei L, Wolfer DP, et al. : Behavioral and anatomical deficits in mice homozygous for a modified β-amyloid precursor protein gene. Cell, 79 : 755-765 (1994).
20) Namba Y, Tomonaga M, Kawasaki H, Otomo E, et al. : Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creuzfeldt-Jakob disease. Brain Res, 541 : 163-166 (1991).
21) Nishiyama E, Iwamoto N, Ohwada J, Arai H : Distribution of apolipo-protein E in senile plaques in brains with Alzheimer's disease ; Investigation with the confocal laser scan microscope. Brain Res, 750 : 20-24 (1997).
22) Nitta A, Itoh A, Hasegawa T, Nabeshima T, et al. : Q-amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett, 170 : 63-66 (1994).
23) Ponte P, Whitt G-D, Schilling J, Miller J, et al. : A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitor. Nature, 331 : 525-527 (1988).
24) Seubert P, Vigo-Pelfrey C, Esch F, Lee M, et al. : Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature, 359 : 325-327 (1992).
25) Shoji M, Hirai S, Yamaguchi H, Harigaya Y, et al. : Amyloid β-protein precursor accumulates in dystrophic neurites of senile plaques in Alzheimer-type dementia. Brain Res, 512 : 164-168 (1990).
26) Shoji M, Golde TE, Ghiso J, Cheung TT, et al. : Production of Alzheimer amyloid β protein by normal proteolytic processing. Science, 258 : 126-129 (1992).
27) Siman R, Card JP, Nelson RB, Davis LG : Expression of β-amyloid precursor protein in reactive astrocytes following neuronal damage. Neuron, 3 : 275-285 (1989).
28) Tamaoka A, Kalaria RN, Lieberburg I, Selkoe D : Identification of a stable fragment of the Alzheimer amyloid precursor containing the β-protein in brain microvessels. Proc Natl Acad Sci USA, 89 : 1345-1349 (1992).
29) Whitson JS, Selkoe DJ, Cotman CW : Amyloid R protein enhances the survival of hippocampal neurons in vitro. Science, 243 : 1488-1490 (1989).
30) Wiraku DO, Bayney R, Ramabhadran TV, et al. : Deposits of amyloid β protein in the central nervous system of transgenic mice. Science, 253 : 323-325 (1991).
31) Yamaguchi H, Hirai S, Morimatsu M, Shoji M, et al. : Avariety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by β protein immunostaing. Acta Neuropathol, 76 : 541-549 (1988).
32) Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, et al. : Neurotoxity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science, 245 : 417-420 (1989).
P.51 掲載の参考文献
1) Askanas V, Engel WK, Bilak M, Alvarez RB, et al. : Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol, 144 : 177-187 (1994).
2) Goedert M, Spillantini MG, Jakes R, Rutherford D, et al. : Multiple isoforms of human microtubule-associated protein tau ; Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron, 3 519-526 (1989).
4) 岩坪威 : アルツハイマー病脳, 老年者脳におけるneuropil threadsおよび神経原線維変化の免疫細胞化学. 神経進歩, 36 : 511-523 (1992).
5) Kondo J, Honda T, Mori H, Hamada Y, et al. : The carboxyl third of tau is tightly bound to paired helical filaments. Neuron, 1 : 827-834 (1988).
6) Lee VM-Y, Balin BJ, Otvos L, Trojanowski JQ : A68 ; A major subunit of paired helical filaments and derivatized forms of normal tau. Science, 251 : 675-678 (1991).
7) Mandelkow E-M, Schweers O, Drewes G, Biernat J, et al. : Structure, microtuble interactions, and phosphorylation of tau protein. Ann N Y Acad Sci, 777 : 96-106 (1996).
8) Matsuo ES, Shin R-W, Billingsley ML, Van de Voorde A, et al. : Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron, 13 : 989-1002 (1994).
9) Mirabelli M, Alvarez RB, Bilak M, Engel WK, et al. : Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol, 55 : 774-786 (1996).
10) Mori H, Kondo J, Ihara Y : Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science, 235 : 1641-1644 (1987).
11) Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, et al. : Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron, 10 : 1151-1160 (1993).
12) Nishimura M, Namba Y, Ikeda K, Oda M : Glial fibrillary tangles with straight tubules in the brains of patients with progressive supranuclear palsy. Neurosci Lett, 143 : 35-38 (1992).
13) Nishimura M, Tommimoto H, Suenaga T, Namba Y, et al. : Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain. Am J Pathol, 146 : 1052-1058 (1995).
14) 西村正樹 : 進行性核上性麻痺とAlzheimer病におけるglial fibrillary tangle. 脳神経, 48 : 895-903 (1996).
15) Shin R-W, Bramblett GT, Lee VM-Y, Trojanowski JQ : Alzheimer disease A68 proteins injected into rat brain induce codeposits of β-amyloid, ubiquitin, and α1-antichymotrypsin. Proc Natl Acad Sci USA, 90 : 6825-6828 (1993).
16) Takashima A, Noguchi K, Sato K, Hoshino T, et al. : Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity. Proc Natl Acad Sci USA, 90 : 7789-7793 (1993).
17) Wille H, Drewes G, Biernat J, Mandelkow E-M, et al. : Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol, 118 : 573-584 (1992).
18) Wood JG, Mirra SS, Pollock NJ, Binder LI : Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (τ). Proc Natl Acad Sci USA, 83 : 4040-4043 (1986).

第3章 生化学的観点から

P.69 掲載の参考文献
1) Arai H, Kobayashi K, Ichimiya Y, Kosaka K, et al. : A preliminary study of free amino acids in the postmortem temporal cortex Alzheimer-type dementia patients. Neurobio Aging, 5 : 319-321 (1984).
2) Arai H, Kosaka K, Iizuka R : Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem, 43 : 388-393 (1984).
3) Arai H, Moroji T, Kosaka K : Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer-type dementia. Neurosci Lett, 52 : 73-78 (1984).
4) Arai H, Emson PC, Mountjoy CQ, Carassco LH, et al. : Loss of parvalbumin-immunoreactive neurones from cortex in Alzheimer-type dementia. Brain Res, 418 : 164-169 (1987).
5) Arai H, Ichimiya Y, Kosaka K, Moroji T, et al. : Neurotransmitter changes in early-and late-onset Alzheimer-type dementia. Neuropsycho Biol Psych, 16 : 883-890 (1992).
6) Atack JR, Perry EK, Bonham JR, Perry RH, et al. : Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type ; Selective loss of the intermediate (10S) form. Neurosci Lett, 40 : 199-204 (1983).
7) Bowen DM, Smith CB, White P, Goodhardt MJ, et al. : Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain, 99 : 459-496 (1976).
8) Brane G, Gottfries CG, Blennow K, Karlsson I, et al. : Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia. Alzheimer Dis Assoc Disord, 3 : 148-156 (1989).
9) Burnstock G : Review lecture ; Neurotransmitters and trophic factors in the autonomic nervous system. J Physiol, 313 : 1-35 (1981).
10) Chan-Palay V : Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease ; A hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol, 273 : 543-557 (1988).
11) Coleman PD, Flood DG : Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging, 8 : 521-545 (1987).
12) Davies P, Maloney AF : Selective loss of central cholinergic neurons in Alzheimer's disease [letter]. Lancet, ii : 1403 (1976).
13) Dawbarn D, Rossor MN, Mountjoy CQ, Roth M : Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type. Neurosci Lett, 70 : 154-159 (1986).
14) Dournaud P, Cervera-Perot P, Hirsch E, Javoy-Agid F, et al. : Somatostatin messenger RNA-containing neurons in Alzheimer's desease ; An in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. Neuroscience, 61 : 755-764 (1994).
15) Gottfries CG, Nyth AL : Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann NY Acad Sci, 640 : 276-279 (1991).
16) Hernandez-Hernandez A, Adam A, Ravid R, Cowburn RF : Preservation of acetylcholine muscasrinic M2 receptor G-protein interactions in the neocortex of patients with Alzheimer's disease. Neurosci Lett, 186 : 57-60 (1995).
17) 小阪憲司, 新井平伊, 小林一成, 稲田雅美 : アルツハイマー型痴呆脳におけるビタミンB12の変化 ; 特にメチルB12について. Dementia, 1 : 65-68 (1987).
18) Kumashiro S, Hashimoto A, Nishikawa T : Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain Res, 681 : 117-125 (1995).
19) Kunugi H, Hattori M, Ueki A, Isse K, et al. : Possible association of missence mutation (Gly [-63] Glu) of the neurotrophin-3 gene with Alzheimer's disease in Japasese. Neurosci Lett, 241 : 65-67 (1998).
20) Lowlor BA, Sunderland T, Mellow AM, Hill JL, et al. : Hyperresponsivity to the serotonin agosist m-chlorphenylpiperazine in Alzheimer's disease. Arch Gen Psychiatory, 46 : 542-549 (1989).
21) Mimori Y, Nakamura S, Yukawa M : Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behav Brain Res, 83 : 25-30 (1997).
22) Minami M, Makino Y, Arai H, Iizuka R : Adisorganized increase of galanin-like immunoreactivity in cerebral cortex of Alzheimer-type dementia brains. J Neural Transm Park Dis Dement Sect, 4 : 285-292 (1991).
23) Mountjoy CQ, Roth M, Evans NJR, Evans HH : Cortical neuronal in normal elderly controls and demented patients. Neurobiol Aging, 4 : 1-11 (1983).
24) Nordberg A, Nilsson-Hakansson L, Adam A, Hardy J, et al. : The role of the nicotinic receptors in the pathophysiology of Alzheimer's desease. Prog Brain Res, 79 : 353-362 (1989).
25) Nordberg A, Hartvig P, Linja A, Viitanen M, et al. : Nicotine receptors in the brain of patients with Alzheimer's disease ; Studies with 11C-nicotine and positron emission tomography. Acta Radiol Suppl (Stockh), 376 : 165-166 (1991).
26) Ohkura T, Isse K, Hamamoto M, Yaoi Y, et al. : Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type ; 7case reports. Dementia, 6 : 99-107 (1995).
27) Pearson RCA, Sofroniew MV, Cuello AC, Powell TPS, et al. : Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res, 289 : 375-379 (1983).
28) Perry EK, Gibson PH, Blessed G, Perry RH, et al. : Neurotranssmiter enzyme abnormalities in senile dementia ; Choline acetyltransferase and glutarnic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci, 34 : 247-265 (1977).
29) Sawada M, Hirata Y, Arai H, Iizuka R, et al. : Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of normal controls and patients with senile dementia of Alzheimer type. J Neurothem, 48 : 760-764 (1987).
30) Shimohama S, Taniguchi T, Fujiwara M, Kameyama M : Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem, 46 : 288-293 (1986).
31) Summers WK, Majovski LV, Marsh GM, Tachiki K, et al. : Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med, 315 : 1241-1245 (1986).
33) Zubenko GS, Moossy J, Kopp U : Neurochemical correlates of major depression in primary dementia. Arch Neurol, 47 : 209-214 (1990).
34) Zubenko GS, Moossy J, Martinez AJ, Rao G, et al. : Neuropatholgic and neurochemical correlates of psychosis in primary dementia. Arch Neurol, 48 : 619-624 (1991).
P.82 掲載の参考文献
1) Arai H, Einson PC, Mountjoy CQ, Carassco LH, et al. : Loss of parvalbumin-immunoreactive neurones from cortex in Alzheimer-type dementia. BYain Res, 418 : 164-169 (1987).
2) Arispe N, Pollard HB, Rojas E : Giant multilevel cation channels formed by Alzheimer disease amyloid β-protein [Aβ P- (1-40) ] in bilayer membranes. Proc Natl Acad Sci U S A, 90 : 10573-10577 (1993).
3) Etcheberrigaray R, Gibson GE, Alkon DL : Molecular mechanisms of memory and the pathophysiology of Alzheimer's disease. Ann N Y Acad Sci U S A, 747 : 245-255 (1994).
4) Hensley K, Carney JM, Mattson MP, Aksenova M, et al. : A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide ; Relevance to Alzheimer disease. Proc Natl Acad Sci, 91 : 3270-3274 (1994).
5) 日高弘義, 間宮均人, 周藤俊樹 : Ca2+ 結合蛋白の機能. CLINICAL NEUROSCIENCE, 14 (2) : 166-170 (1996).
6) Ichimiya Y, Emson PC, Mountjoy CQ, Lawson DEM, et al. : Loss of calbindin-28 K immunoreactive neurones from the cortex in Alzheimer-type dementia. Brain Res, 475 : 156-159 (1988).
7) Ichimiya Y, Emson PC, Mountjoy CQ, Lawson DEM, et al. : Calbindin immunoreactive cholinergic neurones in the nucleus basalis of Meynert in Alzheimer-type dementia. Brain Res, 499 : 402-406 (1989).
8) Ichimiya Y, Arai H, Iizuka R, Emson PC, et al. : Calbindin immunoreactive neurons in Alzheimer-type dementia. In Alzheimer's disease ; Epidemiology, neuropathology, neurochemistry, and clinics, ed. by Maurer K, Riederer P, Beckmann H, 187-192, Springer-Verlag, Wien, New York (1990).
9) 一宮洋介, 新井平伊 : アルツハイマー型痴呆. (本間昭, 武田雅俊編) 臨床精神医学講座第12巻 ; 老年期精神障害, 201-221 中山書店, 東京 (1998).
10) 川原正博, 黒田洋一郎 : Alzheimer β アミロイド神経毒性とアポトーシス. 医学のあゆみ, 176 (10) : 647-649 (1996).
11) 川原茂敬, 井上剛, 桐野豊 : 神経細胞におけるカルシウムイメージング. 細胞, 30 (1) : 7-10 (1998).
12) Mattson MP, Barger SW, Cheng B, Lieberburg I, et al. : β-amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. TINS, 16 : 409-414 (1993).
13) 御小柴克彦, 宮本英七 : 細胞内カルシウムホメオスタシスと細胞機能. 細胞工学, 16 (1) : 10-14 (1997).
14) Nishiyama E, Ohwada J, Iwamoto N, Arai H : Selective loss of calbindin D28K-immunoreactive neurons in the cortical layer II in brains of Alzheimer's disease ; A morphometric study. Neurosci Lett, 163 : 223-226 (1993).
15) 西山悦子 : 記憶の神経回路 ; カルシウム結合蛋白ニューロンネットワーク. CLINICAL CALCIUM, 5 (10) : 1254-1258 (1995).
16) 曽良一郎 : セカンド・メッセンジャー. (小川紀雄編著) 脳のレセプター, 59-74, 世界保健通信社, 大阪 (1986).
17) 内田洋子 : Aβの神経毒性. 神経進歩, 41 (1) : 90-96 (1997).
18) 植松大輔 : 脳虚血とCa2+. CLINICAL NEURO-SCIENCE, 14 (2) : 197-199 (1996).
19) Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, et al. : Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science, 245 : 417-420 (1989).
20) Yankner BA, Duffy LK, Kirschner DA : Neurotrophic and neurotoxic effects of amyloid β protein ; Reversal by tachykinin neuropeptides. Science, 250 : 279-282 (1990).
P.96 掲載の参考文献
1) 秋山治彦 : アルツハイマー病と免疫. 臨床免疫, 25 : 1342-1350 (1993).
2) Akiyama H, Tooyama I, Kimura H, McGeer PL, et al. : Early response of brain resident microglia to kainin acid-induced hippocampal lesions. Brain Res, 635 : 257-268 (1994).
3) Barger SW, Harman AD : Microglial activation by Alzheimer amyroid precursor protein and modulation by apolipoprotein E. Nature, 388 : 878-881 (1997).
4) Blum-began D, Muller T, Kuhn W, Riederer P, et al. : Interleukin-1β and interleukin-6 areelevated in the cerebrospinal fluid of Alzheimer's and novo Parkinson's disease patients. Neurosci Lett, 202 : 17-20 (1995).
5) Breitner JCS, Gau BA, Welsh KA, Anthony JC, et al. : Inverse association of anti-inflammatory treatments and Alzheimer's disease ; Initial results of a co-twin control study. Neurology, 44 : 227-232 (1994).
6) Huell M, Strass S, Volk B, Bauer J, et al. : Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol, 89 : 544-551 (1995).
7) 板垣茂 : アルツハイマー病と補体. 老年精神医学雑誌, 4 : 620-626 (1993).
8) Iwamoto N, Nishiyama E, Ohwada J, Arai H : Demonstration of CRP immunoreactivity in brains of Alzheimer's disease ; Immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett, 177 : 23-26 (1994).
9) McGeer PL, McGeer EG, Rogers J, Sibley J : Anti-inflammatory drugs and Alzheimer's disease. Lancet, 335 : 1037 (1990).
10) McGeer PL, Harada N, Kimura H, et al. : Prevalence of dementia amongst elderly Japanese with leprosy ; Apparent effect of chronic drug therapy. Dementia, 3 : 447-449 (1992).
11) McGeer PL, Rogers J : Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology, 42 : 447-449 (1992).
12) Meda L, Cassatella MA, Szendrei GI, Rossi F, et al. : Activation of microglial cells byβ-amyroid protein and irlterferon-y. Nature, 374 : 647-650 (1995).
13) Namba Y, Kawatsu K, Izumi S, Ikeda K, et al. : Neurofibrillary tangles and senile plaques in brain of elederly leprosy patients. Lancet, 340 : 978 (1992).
14) Rogers J, Kirby LC, Hempelman SR, Willson P, et al. : Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43 : 1609-1611 (1993).
15) Sheng JG, Ito K, Skinner RD, Griffin WST, et al. : In vivo and vitro evidence supporting a role for inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging, 17 : 761-766 (1996).
16) Wyss-foray T, Masliah E, Mallory M, Mucke L, et al. : Amyroidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease. Nature, 389 : 603-606 (1997).

第4章 遺伝学的観点から

P.110 掲載の参考文献
1) Alzheimer's Disease Collaborative Group : The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nature Genetics, 10 : 219-222 (1995).
2) 新井平伊, 柴田展人, 高橋正 : アルツハイマー型痴呆. 最新精神医学, 2 (5) : 439-446 (1997).
3) 朝田隆, 宇野正威, 浅香昭雄 : Alzheimer型痴呆とApo E遺伝子. (高橋徹ほか編) 脳と神経科学シリーズ ; 2. 痴呆解明への新しい展開, 第1版, 117-129, メジカルビュー社, 東京 (1996).
4) Blacker D, Wilcox MA, Laird NM, Rodes L, et al. : Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genetics, 19 : 357-360 (1998).
5) Corder EH, Saunders AM, Strittmatter WJ, Schinechel DE, et al. : Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261 : 921-923 (1993).
6) De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, et al . : Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature, 391 : 387-390 (1998).
7) Duff K, Eckman C, Zehr C, Yu X, et al. : Incresed amyloid-β42 (43) in brains of mice expressing mutant presenilin 1. Nature, 383 : 710-713 (1996).
8) Duff K : Alzheimer transgenic mouse models come of age. Trends Neuroscience, 20 : 279-280 (1997).
9) Games D, Adams D, Alessandrini R, Barbour R, et al. : Alzheimertype neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature, 373 : 523-527 (1995).
10) Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST : APOE4-associated Alzheimer's disease risk is modified by al-antichymotrypsin polymorphism. Nature Genetics, 10 : 486-488 (1995).
11) Matthijs G, Marynen P : Adeletion polymorphism in the human alpha-2-macroglobulin (A2M) gene. Nuceic Acids Res, 19 : 5102 (1991).
12) 三木哲郎 : 痴呆症と遺伝的要因. ブレインサイエンス, 6 : 221-227 (1995).
13) 森啓 : Presenilin 1と2のBiology. 神経進歩, 41 : 18-27 (1997).
14) Murphy GM, Sullivan EV, Thompson G, Thompson LW, et al. : No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease. Neurology, 19 : 1313-1316 (1997).
15) Pericak-Vance MA, Bass ML, Yamaoka LH, Gaskell PC, et al. : Complete genomic screen in late-onset familial Alzheimer's disease. Neurobiol Aging, 19 : 39-42 (1998).
17) 嶋田兼一, 前田潔, 保田稔 : アルツハイマー型痴呆の遺伝子研究, リスクファクターとしてのアポE, ACT遺伝子多型. Dementia Japan, 12 : 53-58 (1998).
18) Suzuki N, Cheung TT, Cai X-D, Okada A, et al. : An incresed percentage of long amyloidβprotein secreted by familial amyloid β protein precursor (β APP 717) mutants. Science, 264 : 1336-1340 (1994).
19) 田平武 : 家族性アルツハイマー病遺伝子プレセニリン1と2. 神経進歩, 41 : 8-17 (1997).
20) Ueki A, Kawano M, Namba Y, Kawakami M, et al. : A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease. Neurosci Lett, 163 : 166-168 (1993).
21) 植木彰 : アポリポ蛋白とアルツハイマー病. Dementia, 10 : 146-158 (1996).
22) Van Broeckhoven C : Presenilins and Alzheimer's disease. Nature Genetics, 11 : 230-232 (1995).
23) 山崎恆夫 : アミロイド前駆蛋白遺伝子とアルツハイマー病. Pharma Medica, 14 : 13-17 (1996).
P.124 掲載の参考文献
1) Alzheimer's Disease Collaborative Group : The structure of the presenilin 1 (S 182) gene and identification of six novel mutations in early onset AD families. Nature Genetics, 10 : 219-222 (1995).
2) 新井平伊, 柴田展人, 高橋正 : アルツハイマー型痴呆. 最新精神医学, 2 (5) : 439-446 (1997).
4) Duff K, Eckman C, Zehr C, Yu X, et aL : Incresed amyloid-β 42 (43) in brains of mice expressing mutant presenilin 1. Nature, 383 : 710-713 (1996).
5) Duff K : Alzheimer transgenic mouse models come of age. Trends Neurosci, 20 : 279-280 (1997).
6) Games D, Adams D, Alessandrini R, Barbour R, et al. : Alzheimertype neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature, 373 : 523-527 (1995).
7) Higuchi S, Muramatsu T, Matsushita S : Presenilin-1 polymorphism and Alzheimer's disease. Lancet, 348 : 1186 (1996).
8) 岩坪威 : Alzheimer病の分子形態. (高橋徹ほか編) 最新脳と神経科学シリーズ ; 2. 痴呆解明への新しい展開, 第1版, 101-116, メジカルビュー社, 東京 (1996).
9) Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST : APOE4-associated Alzheimer's disease risk is modified by α 1-antichymotrypsin polymorphism. Nature Genetics, 10 : 486-488 (1995).
10) 瓦林毅, 東海林幹夫 : トランスジェニックマウスを用いたAlzheimer病モデルの開発. 医学のあゆみ, 174 : 593-597 (1995).
11) 森啓 : Presenilin 1と2のBiology. 神経進歩, 41 : 18-27 (1997).
12) Owen MO, Kehoe P, Williams J : Presenilin-1 polymorphism and Alzheimer's disease. Lancet, 348 : 414 (1996).
13) Shen J, Bronson RT, Chen DF, Xia W, et al. : Skeletal and CNS defects in presenilin-1 deficient mice. Cell, 89 : 629-639 (1997).
15) 柴田展人, 馬場元, 島田秀穂, 新井平伊ほか : 孤発性アルツハイマー型痴呆とpresenilin-1遺伝子イントロン多型の関連について. 精神医学, 40 (6) : 619-622 (1998).
16) 田平武 : 家族性アルツハイマー病遺伝子プレセニリン1と2. 神経進歩, 41 : 8-17 (1997).
17) Tanahashi H, Kawakatsu S, Kaneko M, Yamanaka H, et al. : Sequence analyses of presenilin-1 gene mutation in Japanese Alzheimer's disease patients. Neurosci Lett, 218 : 139-141 (1996).
18) 植木彰 : アポリポ蛋白とアルツハイマー病. Dementia, 10 : 146-158 (1996).
19) Van Broeckhoven C : Presenilins and Alzheimer's disease. Nature Genetics, 11 : 230-232 (1995).
20) Wragg M, Hutton M, Talbot C, Alzheimer's Disease Collaborative Group : Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet, 347 : 509-512 (1996).
P.138 掲載の参考文献
1) Avramopoulos D, Mikkelsen M, Vassilopoulos D, Grigoriadou M, et al. Apolipoprotein E allele distribution in parents of Down's syndrome children. Lancet, 347 : 862-865 (1996).
2) Bergem AL, Lannfelt L : Apolipoprotein E type epsilon 4 allele, heritability and age at onset in twins with Alzheimer disease and vascular dementia. Clin Genet, 52 : 408-413 (1997).
3) Brousseau T, Legrain S, Berr C, Gourlet V, et al. : Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology, 44 : 342-344 (1994).
5) Clatworthy AE, Gomez-lsla T, Rebeck GW, Wallace RB, et al. : Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer disease. Arch Neurol, 54 : 1289-1292 (1997).
6) Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, et al. : Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261 : 921-923 (1993).
8) Farrer LA, Cupples LA, Haines JL, Hyman B, et al. : Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease ; A meta-analysis : APOE and Alzheimer disease meta analysis consortium. JAMA, 278 : 1349-1356 (1997).
9) Gomez-lsla T, West HL, Rebeck GW, Harr SD, et al. : Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol, 39 : 62-70 (1996).
10) Hamaguchi H : Genetic approaches to coronary heart disease. In Genetic risk factors for coronary heart disease in the Japanese population, ed. by Berg K, 110-126, Springer-Verlag, Berlin (1991).
11) Hendrie HC, Hall KS, Hui S, Unverzagt FW, et al. : Apolipoprotein E genotypes and Alzheimer's disease in acommunity study of elderly African Americans. Ann Neurol, 37 : 118-120 (1995).
13) Kamboh MI, Ferrell RE, DeKosky ST : Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene. Neurosci Lett, 244 : 65-68 (1998).
15) Lamb H, Christie J, Singleton AB, Leake A, et al. : Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer's disease and in dementia with Lewy bodies ; Distinctions between diseases. Neurology, 50 : 388-391 (1998).
16) Nacmias B, Marcon G, Tedde A, Forleo P, et al. : Implication of alpha 1-antichymotrypsin polymorphism in familial Alzheimer's disease. Neurosci Lett, 244 : 85-88 (1998).
17) Okuizumi K, Onodera O, Tanaka H, Kobayashi H, et al. : ApoE-epsilon 4 and early-onset Alzheimer's. Nat Genet, 7 : 10-11 (1994).
19) Pericak-Vance MA, Bebout JL, Gaskell PC Jr., Yamaoka LH, et al. : Linkage studies in familial Alzheimer disease ; Evidence for chromosome 19 linkage. Am J Hum Genet, 48 : 1034-1050 (1991).
20) Pickering-Brown SM, Mann DM, Owen F, et al. : Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzheldt-Jakob disease. Neurosci Lett, 187 : 127-129 (1995).
21) Poirier J, Davignon J, Bouthillier D, Kogan S, et al. : Apolipoprotein E polymorphism and Alzheimer's disease. Lancet, 342 : 697-699 (1993).
22) Riekkinen M, Soininen H, Riekkinen P, Sr. , Kuikka J, et al. : Tetrahydroaminoacridine improves the recency effect in Alzheimer's disease. Neuroscience, 83 : 471-479 (1998).
23) Soininen H, Kosunen O, Helisalmi S, Mannermaa A, et al. : A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett, 187 : 79-82 (1995).
24) Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, et al. Apolipoprotein E ; High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset famillial Alzheimer disease. Proc Natl Acad Sci USA, 90 : 1977-1981 (1993).
25) Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, et al. : Binding of human apolipoprotein E to synthetic amyloid beta peptide ; Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl A cad Sci USA, 90 : 8098-8102 (1993).
26) Talbot C, Lendon C, Craddock N, Shears S, et al. : Protection against Alzheimer's disease with apoE epsilion 2. Lancet, 343 : 1432-1433 (1994).
27) Tsai MS, Tangalos EG, Petersen RC, Smith GE, et al. : Apolipoprotein E ; Risk factor for Alzheimer disease. Am J Hum Genet, 54 : 643-649 (1994).
28) Ueki A, Kawano M, Namba Y, Kawakami M, et al. : A high frequency of apolipoprotein E 4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease. Neurosci Lett, 163 : 166-168 (1993).

第5章 臨床的観点から

P.155 掲載の参考文献
1) Abraham CR, Selkoe DJ, Potter H : Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell, 52 : 487-501 (1988).
2) Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, et al. : Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease ; A community based follow up study. J Neurol Neurosurg Psychiatry, 64 : 298-305 (1998).
3) 荒井啓行, 佐藤和彦, 寺嶋正教, 中川琢磨ほか : アルツハイマー病における生物学的診断マーカーとしての脳脊髄液Tau蛋白. 日老医誌, 33 (9) : 669-675 (1996).
4) Brugge K, Katzman R, Hill LR, Hausen LA, et al. : Serological α1-antichymotrypsin in Down's syndrome and Alzheimer's disease. Ann Neurol, 32 : 193-197 (1992).
5) Bush AI, Whyte S, Thomas LD, Masters CL, et al. : An abnormality of plasma amyloid protein precursor in Alzheimer's disease. Ann Neurol, 32 : 57-65 (1992).
6) Henriksson T, Barbour RM, Braa S, Ward P, et al. : Analysis and quantitation of the β-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. J Neurochem, 56 : 1037-1047 (1991).
7) Hock C, Golombowski S, Naser W, Mullerspahn F : Increased levels of τprotein in cerebrospinal fluid of patients with Alzheimer's disease ; Correlation with degree of cognitive impairment. Ann Neurol, 37 : 414-415 (1995).
8) Jensen M, Basun H, Lanfelt L : Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett, 186 : 189-191 (1995).
9) Kitaguchi N, Tokushima Y, Oishi K, Takahashi Y, et al. : Determination of amyloid βprotein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA. Biochem Biophys Res Commun, 166 : 1453-1459 (1990).
10) Matsubara E, Hirai S, Amari M, Shoji M, et al. : α1-antichymotrypsin as a possible biological marker for Alzheimer-type dementia. Ann Neurol, 28 : 561-567 (1990).
11) Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, et al. : Reduction of β-amyloid peptides 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol, 38 : 643-648 (1995).
12) 中村重信 : 老化と関連疾患の神経科学 ; 神経伝達物質. 老年精神医学, 2 : 469-476 (1985).
13) Nakamura T, Shoji M, Harigaya Y, Hosoda K, et al. : Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol, 36 : 903-911 (1994).
14) Nitsch RM, Rebeck GW, Deng M, Growdon JH, et al. : Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease ; Inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol, 37 : 512-518 (1995).
15) Pirttila T, Kim KS, Mehta PD, Wisniewski HM, et al. : Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci, 127 : 90-95 (1994).
16) Prior R, Monning U, Schreiter-Gasser U, Weidemann A, et al. : Quantitative changes in the amyloid β/A 4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett, 124 : 69-73 (1991).
17) Scheuner D, Eckman C, Selkoe D, Younkin S, et al. : Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med, 2 : 864-870 (1996).
18) Shen ZX : CSF cholinesterase activity in demented and non demented subjects. Neuroreport, 9 : 483-488 (1998).
19) Shoji M, Hirai S, Yamaguchi E, Matsubara E, et al. : Alpha 1-antichymotrypsin is present in diffuse senile plaques ; A comparative study of β-protein and α1-antichymotrypsin immunostaining in the Alzheimer brain. Am J Pathol, 138 : 247-257 (1991).
20) Urakami K, Takahashi K, Okada A, Oshima T, et al. : Clinical course and CSF amyloid β protein precursor having the site of application of the protease inhibitor (APPI) levels in patients with dementia of the Alzheimer type. Dementia, 4 : 59-60 (1993).
21) Vandermeeren M, Mercken M, Vanmechelen E, Six J, et al. : Detection of τproteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem, 61 : 1828-1834 (1993).
P.168 掲載の参考文献
1) Belliveau JW, Kennedy DN, McKinstry RC, Buchbinder BR, et al. : Functionnal mapping of the human visual cortex by magnetic resonance imaging. Science, 254 : 716-719 (1991).
2) Bonte FJ, Devous MD Sr, Reisch JS, Ajmani AK, et al. : The effect of acetazolamide on regional cerebral blood flow in patients with Alzheimer's disease or stroke as measured by single-photon emission computed tomography. Invest Radiol, 24 (2) : 99-103 (1989).
3) Corkin S : Functional MRI for studying episodic memory in aging and Alzheimer's disease. Geriatrics, 53 [Suppl. 1] 13-15 (1998).
4) Cuenod CA, Bookheimer SY, Hertz-Pannier L, Zeffiro TA, et al. : Functional MRI during word generation, using conventional equipment ; Potential tool for language localization in the clinical environment. Neurology, 45 : 1821-1827 (1995).
5) Cutler NR, Haxby JV, Duara R, Grady CL, et al. : Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease. Ann Neurol, 18 : 298-309 (1985).
6) Foster NL, Chase TN, Mansi L, Brooks R, et al. : Cortical abnormalities in Alzheimer's disease. Ann Neurol, 16 : 649-654 (1984).
7) Fox PT, Raichle ME : Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subject. Proc Natl Acad Sci U S A, 83 : 1140-1144 (1986).
8) Fukuyama H, Ogawa M, Yamauchi H, Ymaguchi S, et al. : Altered cerebral energy metabolism in Alzheimer's disease ; A PET study. J Nucl Med, 35 : 1-6 (1994).
9) Gonzalez RG, Fishman AJ, Guimaraes AR, Carr CA, et al. : Functional MR in the evaluation of dementia ; Correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with Fludeoxyglucose F 18. Am J Neuroradiol, 16 : 1763-1770 (1995).
10) Gray W, John CM, Mark TC, Lewis RB, et al. : Apolipoprotein E type 4 allele and cerebral glucose metabolism in relative at risk for familial Alzheimer disease. JAMA, 273 : 942-947 (1995).
11) Haxby JV, Grady CL, Duara R, Schlageter N, et al. : Neocortical metabolic abnormalities precede nonmemory cognitive deficits in early Alzheimer's-type dementia. Arch Neurol, 43 (9) : 882-885 (1986).
12) Ibanez V, Pietrini P, Alexander GE, Furey ML, et al. : Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology, 50 (6) : 1585-1593 (1998).
13) Iyo M, Namba H, Fukushi K, Shinotoh H, et al. : Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet, 349 : 1805-1809 (1997).
14) 北村伸, 酒寄修, 越泰彦 (赫彰郎監修) : 痴呆性疾患の画像診断シリーズ (1) ; アルツハイマー型痴呆. 24-31, ワールドプランニング, 東京 (1997).
15) Kleinschmidt A, Steinmetz H, Sitzer M, Merboldt KD, et al. : Magnetic resonance imaging of regional cerebral blood oxygenation changes under acetazolamide in carotid occlusive disease. Stroke, 26 : 106-110 (1995).
16) Sugishita M, Takayama Y, Shiono T, Yoshikawa K, et al. : Functional magnetic resonance imaging (fMRI) during mental writing with phonograms. Neuroreport, 7 : 1917-1921 (1996).
17) Yamaguchi S, Meguro K, Itoh M, Hayasaka C, et al. : Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. JNNP, 62 : 596-600 (1997).
P.194 掲載の参考文献
1) Arai H, Kosaka K, Iizuka R : Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem, 43 : 388-393 (1984).
2) 新井平伊, 石井毅 : 抗痴呆薬の種類と考え方. 臨床精神医学, 18 : 1027-1032 (1989).
3) 新井平伊, 高橋正, 柴田展人 : アルツハイマー型痴呆の病因と治療 ; 現況と展望. 精神神経学雑誌, 99 : 822-828 (1997).
4) Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, et al. : Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet, 337 : 1304-1308 (1991).
5) Davies P, Maloney AJ : Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, ii : 1403 (1976).
6) Fillit H, Weinreb H, Cholst I, Luine V, et al. : Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology, 11 : 337-345 (1986).
7) Harkins SW, Taylor JR, Mattay VS : Response to tacrine in patients with dementia of the Alzheimer's type ; Cerebral perfusion change is related to change in mental status. Int J Neurosci, 84 : 149-156 (1996).
9) Jette N, Cole MS, Fahnestock M : NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Mol Brain Res, 25 : 242-250 (1994).
10) Kilpatrick GJ, Jones BJ, Tyers MB : Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature, 330 : 746-748 (1978).
12) Lyketsos CG, Corazzini K, Steele CD, Kraus MF : Guidelines for the use of tacrine in Alzheimer's disease ; Clinical application and effectiveness. J Neuropsychiatry Clin Neurosci, 8 : 67-73 (1996).
13) McGeer PL, Rogers J : Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology, 42 : 447-449 (1992).
15) Perry EK, Tomlinson BE, Blessed G, Bergmann K, et al. : Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J, 2 : 1457-1459 (1978).
16) Poirier J, Delisle MC, Quirion R, Aubert I, et al. : Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A, 92 : 12260-12264 (1995).
17) Rogers SL, Farlow MR, Doody RS, Mohs R, et al. : A24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50 : 136-145 (1998).
19) Summers WK, Majovski LV, Marsh GM, Tachiki K, et al. : Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med, 315 : 1241-1245 (1986).
20) 高橋正, 新井平伊 : 痴呆の薬物療法 ; 抗痴呆薬開発の現状. (平井俊策編) よくわかって役に立つ ; 痴呆症のすべて, 183-200, 永井書店, 大阪 (2000).
21) Watson M, Vickroy TW, Roeske WR, Yamamura HI : Functional and biochemical basis for multiple muscarinic acetylcholine receptors. Prog Neuropsychopharmacol Biol Psychiatry, 9 : 569-574 (1985).

第6章 関連疾患 : 他の初老期痴呆

P.212 掲載の参考文献
1) Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, et al. : Genetic evidence for the involvement of τ in progressive supranuclear palsy. Ann Neurol, 41 : 41 : 277-281 (1998).
2) Delacourte A, Sergeant N, Wattez A, Gauvreau D, et al. : Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their τ isoform distribution and phosphorylation. Ann Neurol, 43 : 193-204 (1998).
3) de la Monte SM, Sohn YK, Ganju N, Wands JR : p53-and CD 95-associated apoptosis in neurodegenerative diseases. Lab Invest, 78 : 401-411 (1998).
4) Dickson DW, Yen S-H, Suzuki KI, Davies P, et al. : Ballooned neurons in select neurodegenerative disease contain phosphorylated neurofilament epitopes. Acta Neuropathol, 71 : 216-223 (1986).
5) Dumanchin C, Camuzat A, Campion D, Verpillat P, et al. : Segregation of a missense mutation in the microtuble-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet, 7 1825-1829 (1998).
6) Giannakopoulos P, Kovari E, Buee L, Shioi J, et al. : Presenilin-1 expression in Pick's disease. Acta Neuropathol, 98 : 488-492 (1999).
7) Gleckman AM, Jiang 2, Liu Y, Smith TW : Neuronal and glial DNA fragmentation in Pick's disease. Acta Neuropathol, 98 : 55-61 (1999).
8) Goedert M, Jakes R, Spillantini MG, Hasegawa M, et al. : Sulphated glycosaminoglycans induce assembly of microtuble-assiciated protein tau into Alzheimer-like filaments. Nature, 383 : 550-553 (1996).
9) Goedert M : Filamentous nerve cell inclusions in neurodegenerative disease : tauopathies and α-synuclein opathies Phil Trans R Soc Lond B, 354 : 1101-1118 (1999).
10) Hollister RD, Xia M, McNamara MJ, Hyman BT : Neuronal expression of class II major histocompatibility complex (HLA-DR) in 2 cases of Pick disease. Arch Neurol, 54 : 243-248 (1997).
12) Iijima M, Tabira T, Poorkaj P, Schellenberg GD, et al. : A distinct familial presenile dementia with a novel missense mutation in the tau gene. Neuroreport, 10 : 497-501 (1999).
13) Kanazawa I, Kwak S, Sasaki H, Muramoto O, et al. : Studies on the neurotransmitter markers of the basal ganglia in Pick's disease with special reference to dopamine reduction. J Neurol Sci, 83 : 63-74 (1988).
14) Meda L, Cassatella MA, Szendrei GI, Otvos L, et al . : Activation of microglial cells by β-amyroid protein and interferon-γ. Nature, 374 : 647-650 (1995).
15) Nakamura Y, Takeda M, Yoshimi K, Hattori H, et al . : Involvement of clathrin light chains in the pathology of Pick's disease ; Implications for impairment of axonal transport. Neurosci Lett, 180 : 25-28 (1994).
16) Nishimura M, Tomimoto H, Suenaga T, Namba Y, et al. : Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain. Am J Pathol, 146 : 1052-1058 (1995).
17) Probst A, Tolnay M, Langui D, Goedert M, et al. : Pick's disease ; Hyperphosphorylated tau protein segregates to somatoaxonal compartment. Acta Neuropathol, 92 : 588-596 (1996).
18) Sergeant N, David JP, Lefranc D, Vermersch P, et al. : Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett, 412 : 578-582 (1997).
19) Singhrao SK, Neal JW, Gasque P, Morgan BP, et al. : Role of complement in the aetiology of Pick's disease? J Neuropathol Exp Neurol, 55 : 578-593 (1996).
20) Spillantini MG, Bird TD, Ghetti B : Frontotemporal dementia and parkinsonism linked to chromosome 17 ; A new group of tauopathies. Brain Pathol, 8 : 387-402 (1998).
21) Spillantini MG, Murrell JR, Goedert M, Farlow MR, et al. : Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA, 95 : 7737-7741 (1998).
22) Taupenot L, Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, et al. : Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience, 72 : 377-389 (1996).
23) Yasuhara O, Kawamata T, Aimi Y, McGeer EG, et al. : Expression of chromagranin A in lesions in the central nervous system from patients with neurological diseases. Neurosci Lett, 170 : 13-16 (1994).
P.225 掲載の参考文献
1) 赤井淳一郎 : クロイツフェルトヤコブ病. 神経精神疾患モノグラフシリーズ 8, 星和書店, 東京 (1984),
2) Demaerel P, Heiner L, Robberecht W, Sciot R, et al. : Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology, 52 (1) : 205-208 (1999).
4) Gibbs CJ Jr, Gajdusek DC, Asher DM, Alpers MP, et al. : Creutzfeldt-Jakob disease (spongiform encephalopathy) ; Transmission to the chimpanzee. Science, 161 : 388-389 (1968).
5) 一宮洋介 : プリオン病とアルツハイマー病. Pharma Medica, 14 (11) : 67-76 (1996).
6) 一宮洋介 : セカンドメッセンジャー・カルシウム代謝異常. 老年精神医学雑誌, 9 (10) : 1229-1235 (1998).
7) 川原正博 : アミロイドの神経毒性 ; アルツハイマー病, プリオン病, トリプレットリピート病の関連. Brain Medical, 9 (3) : 263-268 (1997).
8) 川島敏郎, 堂浦克美 : プリオンタンパクの異常と神経疾患. 老年精神医学雑誌, 9 (3) : 260-264 (1998).
9) King CY, Tittmann P, Gross H, Geber R, et al. : Prion-inducing domain 2-114 of yeast Sup 35 protein transformations in vitro into amyloid-like filaments. Proc Natl Acad Sci U S A, 94 (13) : 6618-6622 (1997).
10) 北本哲之 : プリオン病の分子病理. Dementia, 8 (4) : 357-362 (1994).
11) 厚生省保健医療局疾病対策課 (監) : クロイツフェルト・ヤコブ病診療マニュアル. 12, 新企画出版社, 東京 (1997).
12) Lin M-C, Mirzabekov T, Kagan BL : Channel formation by a neurotoxic prion protein fragment. J Biol Chem, 272 (1) : 44-47 (1997).
13) 小野文一郎 : 酵母のプリオン様細胞質性遺伝因子 ; 蛋白質のコンフォメーションと生物機能. 蛋白質・核酸・酵素, 40 (15) : 2320-2328 (1995).
14) Prusiner SB : Novel proteinaceous infectious particles cause scrapie. Science, 216 : 136-144 (1982).
16) 佐藤猛, 星研一, 増田真也, 吉野英ほか : 医原性プリオン病 ; ヒト硬膜移植後に発病したクロイツフェルト・ヤコブ病. 神経進歩, 43 (1) : 145-154 (1999).
17) 宇高不可思, 藤澤道子, 亀山正邦 : Creutzfeldt-Jakob病 (CJD), Gerstmann-Straussler-Scheinker (GSS) 症候群. 日本臨床, 55 (4) : 972-977 (1997).
18) 氏家 寛, 黒田重利 : ゲルストマン-ストロイスラー-シャインカー病. 老年精神医学雑誌, 9 (3) : 271-279 (1998).
19) Wickner RB : [URE 3] as an altered URE 2 protein ; Evidence for a prion analog in Saccharomyces cerevisiae. Science, 264 : 566-569 (1994).
20) Will RG, Ironside JW, Zeidler M, Cousens SN, et al. : A new variant of Creutzfeldt-Jakob disease in the UK. Lancet, 347 : 921-925 (1996).
P.240 掲載の参考文献
1) Albin RL, Minoshima S, D'Amato CJ, Frey KA, et al. : Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology, 47 (2) : 462-466 (1996).
2) Atkinson A, Singleton AB, Steward A, Ince PG, et al. : CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy bodies or Alzheimer's disease. Pharmacogenetics, 9 (1) : 31-35 (1999).
3) Baba M, Nakajo S, Tu PH, Tomita T, et al. : Aggregation of alpha synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol, 152 (4) : 879-884 (1998).
6) Crowther RA, Jakes R, Spillantini MG, Goedert M : Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett, 436 (3) : 309-312 (1998).
7) 池田研二 : びまん性レビー小体病と痴呆. 老年精神医学雑誌, 4 (10) : 1124-1128 (1993).
8) 井関栄三 : びまん性レビー小体病. 精神科治療学, 14 (増刊号) : 91-94 (1999).
9) Iwatubo T, Yamaguchi H, Fujimuro M, Yokosawa H, et al. : Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol, 148 : 1517-1529 (1996).
10) 河西千秋, 井関栄三, 小田原俊成, 大西秀樹ほか : びまん性レビー小体病とアポリポ蛋白E. Dementia, 10 : 159-163 (1996).
11) 小阪憲司, 松下正明, 小柳新策, Mehraein P : Lewy小体病の臨床神経病理学的研究. 精神経誌, 82 (5) : 292-311 (1980).
12) 小阪憲司 : レビー小体型痴呆. Dementia, 10 (4) : 365-371 (1996).
13) 小阪憲司, 井関栄三 : 非アルツハイマー型変性痴呆の最近の動向. 精神医学, 41 (3) : 234-246 (1999).
14) 小阪憲司 : びまん性Lewy小体病. 神経内科, 50 : 146-150 (1999).
15) Lebert F, Pasquier F, Souliez L, Petit H : Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry, 13 (8) : 516-519 (1998).
16) Lippa CF, Smith TW, Saunders AM, Crook R, et al. : Apolipoprotein E genotype and Lewy body disease. Neurology, 45 (1) : 97-103 (1995).
18) McKeith IG, Galasko D, Kosaka K, Perry EK, et al. : Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Neurology, 47 : 1113-1124 (1996).
19) Mega MS, Masterman DL, Benson DF, Vinters HV, et al. : Dementia with Lewy bodies ; Reliability and validity of clinical and pathologic criteria. Neurology, 47 (6) : 1403-1409 (1996).
20) Perry EK, Haroutunian V, Davis KL, Levy R, et al. : Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport, 5 (7) : 747-749 (1994).
21) Perry EK, Morris CM, Court JA, Cheng A, et al. : Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease ; Possible index of early neuropathology. Neuroscience, 64 (2) 385-395 (1995).
22) Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, et al. : Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science, 274 (5290) : 1197-1199 (1996).
23) Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, et al. : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276 (5321) : 2045-2047 (1997).
26) St. Clair D : Apolipoprotein E gene in Parkinson's disease, Lewy body dementia and Alzheimer's disease. J Neural Transm Suppl, 51 : 161-165 (1997).

最近チェックした商品履歴

Loading...